Limits...
CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis.

Mir F, Lee D, Ray H, Sadiq SA - Neurol Neuroimmunol Neuroinflamm (2014)

Bottom Line: We found increased CSF levels of 8-iso-PGF2α in patients with MS compared to controls, with the most striking values in a subgroup of patients with SPMS.Furthermore, the increase in 8-iso-PGF2α correlated with other parameters of lipid peroxidation as well as with a decrease in the total antioxidant status in the MS CSF samples.Further investigation will help establish the pathologic and clinical significance of our preliminary findings.

View Article: PubMed Central - PubMed

Affiliation: Tisch MS Research Center of New York, New York, NY.

ABSTRACT

Objective: To investigate the potential of 8-iso-prostaglandin F2α (8-iso-PGF2α) as a biomarker for disease activity and oxidative stress in the CSF of patients with multiple sclerosis (MS).

Methods: The isoprostane 8-iso-PGF2α is an established biomarker for in vivo oxidative stress and lipid peroxidation. We measured CSF 8-isoPGF2α levels in 231 patients with MS (74 with relapsing-remitting MS, 67 with primary progressive MS, and 90 with secondary progressive MS [SPMS]) and 40 controls using a competition ELISA.

Results: We found increased CSF levels of 8-iso-PGF2α in patients with MS compared to controls, with the most striking values in a subgroup of patients with SPMS. Furthermore, the increase in 8-iso-PGF2α correlated with other parameters of lipid peroxidation as well as with a decrease in the total antioxidant status in the MS CSF samples.

Conclusions: Our study demonstrates that CSF levels of 8-iso-PGF2α may serve as a biomarker of oxidative stress in MS. Further investigation will help establish the pathologic and clinical significance of our preliminary findings.

No MeSH data available.


Related in: MedlinePlus

8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A) 8-Iso-PGF2α levels in the multiple sclerosis (MS) subgroups compared to normal healthy controls and other neurologic disease controls. (B) Isoprostane levels as a function of disease activity in active vs inactive patients with secondary progressive MS. (C) Comparison of 8-iso-PGF2α levels in CSF with serum from the patients with MS. (D) Levels of 8-iso-PGF2α in CSF from untreated patients with MS. (E) Changes in 8-iso-PGF2α levels over an 18-month period in a group of 23 patients with MS. Groups were statistically compared using GraphPad Prism 5.0. * indicates statistical significance with a p value of <0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4202929&req=5

Figure 1: 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A) 8-Iso-PGF2α levels in the multiple sclerosis (MS) subgroups compared to normal healthy controls and other neurologic disease controls. (B) Isoprostane levels as a function of disease activity in active vs inactive patients with secondary progressive MS. (C) Comparison of 8-iso-PGF2α levels in CSF with serum from the patients with MS. (D) Levels of 8-iso-PGF2α in CSF from untreated patients with MS. (E) Changes in 8-iso-PGF2α levels over an 18-month period in a group of 23 patients with MS. Groups were statistically compared using GraphPad Prism 5.0. * indicates statistical significance with a p value of <0.05.

Mentions: 8-Iso-PGF2α levels in the CSF were measured in 231 patients with MS and 40 controls (table) using a competitive ELISA. As a group, the mean value of 8-iso-PGF2α levels in the CSF of the patients with MS (43 pg/mL; RRMS: 15.5 ± 7.9, PPMS: 25 ± 11.8, SPMS: 79 ± 86.9) was higher (p value <0.0001) than the mean value of healthy control samples (8.7 ± 1.6 pg/mL) and the OND control group (10.6 ± 4.5 pg/mL). The range of 8-iso-PGF2α CSF levels varied greatly among patients with MS, with several patients with RRMS, SPMS, and PPMS having levels greater than 20 pg/mL, a level not exceeded by any control (figure 1A). As a group, patients with progressive disease had higher values than those with RRMS, and only patients with SPMS had values greater than 100 pg/mL. This difference, however, is compounded by the inherent differences between the 2 groups in terms of age, disease duration and severity (table), and disease-modifying therapies.


CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis.

Mir F, Lee D, Ray H, Sadiq SA - Neurol Neuroimmunol Neuroinflamm (2014)

8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A) 8-Iso-PGF2α levels in the multiple sclerosis (MS) subgroups compared to normal healthy controls and other neurologic disease controls. (B) Isoprostane levels as a function of disease activity in active vs inactive patients with secondary progressive MS. (C) Comparison of 8-iso-PGF2α levels in CSF with serum from the patients with MS. (D) Levels of 8-iso-PGF2α in CSF from untreated patients with MS. (E) Changes in 8-iso-PGF2α levels over an 18-month period in a group of 23 patients with MS. Groups were statistically compared using GraphPad Prism 5.0. * indicates statistical significance with a p value of <0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4202929&req=5

Figure 1: 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A) 8-Iso-PGF2α levels in the multiple sclerosis (MS) subgroups compared to normal healthy controls and other neurologic disease controls. (B) Isoprostane levels as a function of disease activity in active vs inactive patients with secondary progressive MS. (C) Comparison of 8-iso-PGF2α levels in CSF with serum from the patients with MS. (D) Levels of 8-iso-PGF2α in CSF from untreated patients with MS. (E) Changes in 8-iso-PGF2α levels over an 18-month period in a group of 23 patients with MS. Groups were statistically compared using GraphPad Prism 5.0. * indicates statistical significance with a p value of <0.05.
Mentions: 8-Iso-PGF2α levels in the CSF were measured in 231 patients with MS and 40 controls (table) using a competitive ELISA. As a group, the mean value of 8-iso-PGF2α levels in the CSF of the patients with MS (43 pg/mL; RRMS: 15.5 ± 7.9, PPMS: 25 ± 11.8, SPMS: 79 ± 86.9) was higher (p value <0.0001) than the mean value of healthy control samples (8.7 ± 1.6 pg/mL) and the OND control group (10.6 ± 4.5 pg/mL). The range of 8-iso-PGF2α CSF levels varied greatly among patients with MS, with several patients with RRMS, SPMS, and PPMS having levels greater than 20 pg/mL, a level not exceeded by any control (figure 1A). As a group, patients with progressive disease had higher values than those with RRMS, and only patients with SPMS had values greater than 100 pg/mL. This difference, however, is compounded by the inherent differences between the 2 groups in terms of age, disease duration and severity (table), and disease-modifying therapies.

Bottom Line: We found increased CSF levels of 8-iso-PGF2α in patients with MS compared to controls, with the most striking values in a subgroup of patients with SPMS.Furthermore, the increase in 8-iso-PGF2α correlated with other parameters of lipid peroxidation as well as with a decrease in the total antioxidant status in the MS CSF samples.Further investigation will help establish the pathologic and clinical significance of our preliminary findings.

View Article: PubMed Central - PubMed

Affiliation: Tisch MS Research Center of New York, New York, NY.

ABSTRACT

Objective: To investigate the potential of 8-iso-prostaglandin F2α (8-iso-PGF2α) as a biomarker for disease activity and oxidative stress in the CSF of patients with multiple sclerosis (MS).

Methods: The isoprostane 8-iso-PGF2α is an established biomarker for in vivo oxidative stress and lipid peroxidation. We measured CSF 8-isoPGF2α levels in 231 patients with MS (74 with relapsing-remitting MS, 67 with primary progressive MS, and 90 with secondary progressive MS [SPMS]) and 40 controls using a competition ELISA.

Results: We found increased CSF levels of 8-iso-PGF2α in patients with MS compared to controls, with the most striking values in a subgroup of patients with SPMS. Furthermore, the increase in 8-iso-PGF2α correlated with other parameters of lipid peroxidation as well as with a decrease in the total antioxidant status in the MS CSF samples.

Conclusions: Our study demonstrates that CSF levels of 8-iso-PGF2α may serve as a biomarker of oxidative stress in MS. Further investigation will help establish the pathologic and clinical significance of our preliminary findings.

No MeSH data available.


Related in: MedlinePlus